Immedica publishes key study on societal impact of ARG1-D
Stockholm, September 25, 2024 – Immedica is pleased to announce the publication of its sponsored study, "Societal Costs and Quality of Life Associated with Arginase 1 Deficiency (ARG1-D) in a European Setting – A Multinational, Cross-Sectional Survey", in the Journal of Medical Economics1. The study provides valuable insights into the societal costs and quality of life impacts of ARG1-D, an ultra-rare disease, causing progressive mobility and cognitive impairments. Data was collected from patients and caregivers across four European countries: France, Portugal, Spain, and the United Kingdom.
The study marks a significant step in understanding the broader societal burden of ARG1-D, shedding light on the real-world challenges faced by patients and their families. It underscores the critical need for innovative treatments and comprehensive support for those living with this ultra-rare condition.
“This study provides crucial insights into the challenges faced by ARG1-D patients and their families, reaffirming the need for continued innovation. As we expand our health economic function, we are focused on generating and analyzing relevant data to support the value of our products. This growing capability allows us to translate these findings into actionable steps that inform better clinical practices, improve healthcare decisions, and ultimately enhance the lives of those impacted by rare diseases”, said Lena Jacobson, Head of Market Access and Health Economics at Immedica.
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018 and employs today more than 120 people across Europe, the Middle East and the U.S. The main owners are the investment firms KKR and Impilo.
For more information visit www.immedica.com
Immedica contact:
Linda Holmström
Global Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95
Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm